Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery.

Broglio F, Guarracino F, Benso A, Gottero C, Prodam F, Granata R, Avogadri E, Muccioli G, Deghenghi R, Ghigo E

European journal of pharmacology1 Jul 2002Cited by 20 (Europe PMC)

PMID12144941DOI10.1016/s0014-2999(02)01934-9PepBankPUB-12144941

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, hexarelin increased left ventricular ejection fraction from 10 minutes, while rhGH, GHRH and placebo had no hemodynamic effect.
In plain wordsIn patients having heart bypass surgery, hexarelin raised the heart's pumping fraction, but GH, GHRH and placebo did not.
Peptide
Hexarelin
Outcome
IncreaseLeft ventricular ejection fraction
Study
n: not reported in source
Comparator
Placebo, GHRH, rhGH
Outcome group
Heart function · Cardiovascular
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
RhGH, GHRH and placebo did not exert any hemodynamic effect while hexarelin induced a prompt (after +10 min) increase in left ventricular ejection fraction (P < 0.001), cardiac index (P < 0.001) and cardiac output (P < 0.001) lasting up to +90 min without any variation in left ventricular end diastolic volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494101
02HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, hexarelin increased cardiac index up to +90 min, while rhGH, GHRH and placebo had no hemodynamic effect.
In plain wordsIn patients having heart bypass surgery, hexarelin raised cardiac index, but GH, GHRH and placebo did not.
Peptide
Hexarelin
Outcome
IncreaseCardiac index
Study
n: not reported in source
Comparator
Placebo, GHRH, rhGH
Outcome group
Heart function · Cardiovascular
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
RhGH, GHRH and placebo did not exert any hemodynamic effect while hexarelin induced a prompt (after +10 min) increase in left ventricular ejection fraction (P < 0.001), cardiac index (P < 0.001) and cardiac output (P < 0.001) lasting up to +90 min without any variation in left ventricular end diastolic volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494102
03HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, hexarelin increased cardiac output up to +90 min, while rhGH, GHRH and placebo had no hemodynamic effect.
In plain wordsIn patients having heart bypass surgery, hexarelin raised cardiac output, but GH, GHRH and placebo did not.
Peptide
Hexarelin
Outcome
IncreaseCardiac output
Study
n: not reported in source
Comparator
Placebo, GHRH, rhGH
Outcome group
Heart function · Cardiovascular
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
RhGH, GHRH and placebo did not exert any hemodynamic effect while hexarelin induced a prompt (after +10 min) increase in left ventricular ejection fraction (P < 0.001), cardiac index (P < 0.001) and cardiac output (P < 0.001) lasting up to +90 min without any variation in left ventricular end diastolic volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494103
04HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, hexarelin caused no variation in left ventricular end diastolic volume.
In plain wordsIn patients having heart bypass surgery, hexarelin did not change the filling volume of the left heart chamber.
Peptide
Hexarelin
Outcome
No significant changeLeft ventricular end diastolic volume
Study
n: not reported in source
Comparator
Placebo, GHRH, rhGH
Outcome group
Heart function · Cardiovascular
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
without any variation in left ventricular end diastolic volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494104
05HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, hexarelin reduced wedge pressure.
In plain wordsIn patients having heart bypass surgery, hexarelin lowered wedge pressure, a measure of pressure in the heart.
Peptide
Hexarelin
Outcome
DecreaseWedge pressure
Study
n: not reported in source
Comparator
Placebo, GHRH, rhGH
Outcome group
Heart function · Cardiovascular
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
Accordingly, hexarelin induced a reduction of wedge pressure (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494105
06HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, hexarelin was associated with increased mean arterial pressure.
In plain wordsIn patients having heart bypass surgery, hexarelin was linked to higher mean arterial blood pressure.
Peptide
Hexarelin
Outcome
IncreaseMean arterial pressure
Study
n: not reported in source
Comparator
Placebo, GHRH, rhGH
Outcome group
Blood pressure · Cardiovascular
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
These changes occurred in the presence of increased mean arterial pressure (P < 0.05) and transient decrease of central venous pressure (P < 0.05 at +30 min only) but no change in systemic vascular resistance index.
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494106
07HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, hexarelin was associated with a transient decrease of central venous pressure, at +30 min only.
In plain wordsIn patients having heart bypass surgery, hexarelin briefly lowered central venous pressure.
Peptide
Hexarelin
Outcome
DecreaseCentral venous pressure
Study
n: not reported in source
Comparator
Placebo, GHRH, rhGH
Outcome group
Blood pressure · Cardiovascular
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
These changes occurred in the presence of increased mean arterial pressure (P < 0.05) and transient decrease of central venous pressure (P < 0.05 at +30 min only) but no change in systemic vascular resistance index.
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494107
08HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, hexarelin caused no change in systemic vascular resistance index.
In plain wordsIn patients having heart bypass surgery, hexarelin did not change resistance to blood flow in the body's vessels.
Peptide
Hexarelin
Outcome
No significant changeSystemic vascular resistance index
Study
n: not reported in source
Comparator
Placebo, GHRH, rhGH
Outcome group
Blood pressure · Cardiovascular
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
These changes occurred in the presence of increased mean arterial pressure (P < 0.05) and transient decrease of central venous pressure (P < 0.05 at +30 min only) but no change in systemic vascular resistance index.
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494108
09HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, heart rate after hexarelin was similar to that after placebo.
In plain wordsIn patients having heart bypass surgery, heart rate after hexarelin was similar to heart rate after placebo.
Peptide
Hexarelin
Outcome
No significant changeHeart rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
Heart rate after hexarelin was similar to that after placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494109
10HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, hexarelin slightly increased GH levels, similar to the increase after GHRH.
In plain wordsIn patients having heart bypass surgery, hexarelin slightly raised growth hormone, about as much as GHRH did.
Peptide
Hexarelin
Outcome
IncreaseGH levels versus GHRH
Study
n: not reported in source
Comparator
GHRH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
Hexarelin induced a slight increase in GH levels which was similar to that after GHRH
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494110
11HumanNon-randomized trialEfficacy outcome
In patients with coronary artery disease undergoing by-pass surgery, the GH level after hexarelin was far lower than that after rhGH.
In plain wordsIn patients having heart bypass surgery, growth hormone levels after hexarelin were far lower than after injected growth hormone.
Peptide
Hexarelin
Outcome
DecreaseGH levels versus rhGH
Study
n: not reported in source
Comparator
rhGH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2.0 microg/kg · i.v.As given in this study (human).
Source sentences
Summary
but far lower (P < 0.01) than that after rhGH.
1 context sentence(design, population, supporting numbers)
Summary · context
Cardiac performance was studied in 24 male patients (age [mean +/- S.E.M.]: 59.5 +/- 1.1 years; body mass index: 24.6 +/- 0.9 kg/m(2); left ventricular ejection fraction: 57.2 +/- 1.4%) with coronary artery disease undergoing by-pass surgery during general anesthesia.
Report a problemFND-1214494111

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.